F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Develop Next-Generation Multi-Specific Antibodies

F-star Therapeutics, an invoX company, has announced a strategic collaboration and license agreement with Takeda to discover and develop next-generation multi-specific antibodies. The collaboration will focus on using F-star's proprietary platforms to research and develop immunotherapies for cancer patients. Under the agreement, F-star and Takeda will work together to research and develop novel ..